Myriad International Gmbh

Siemens Healthcare Diagnostics Gmbh

Other

Sividon Diagnostics Gmbh

Bayer Healthcare Aktiengesellschaft

Mathias Gehrmann

Guido Hennig

Ralf Kronenwett

Christoph Petry

Werner Kroll

Christian Von Törne

Karsten Weber

Inke Sabine Feder

Mareike Dartmann

Andreas Knorr

Detlef Schuppan

Elmar-Reinhold Burchardt

Johannes-Peter Stasch

Berthold Hocher

Massimo Pinzani

Sylvia Unger

Michael J Arthur

Alastair D Burt

Robert P Thiel

Jan Brase

William Rosenberg

Karin Fisch

Elmar Reinhold Burchardt

Werner Schröder

Marcus Schmidt

Michael Volker

Michael Becka

Guido Henning

The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.

Method for breast cancer recurrence prediction under endocrine treatment

The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising:

Described herein are methods for predicting a benefit from inclusion of taxane in a chemotherapy regimen in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer. Said method includes the steps of determining the expression levels of the marker genes S100P and PCSK6 and mathematically combining the expression level values to yield a combined score and comparing said combined score to a reference-value, wherein a high combined score is indicative of a benefit from including a taxane in a chemotherapy regimen of said patient and a low combined score is indicative of not having a benefit from including a taxane in a chemotherapy regimen.

Method for predicting the benefit from inclusion of taxane in a chemotherapy regimen in patients with breast cancer

The invention provides diagnostic methods, kits, and systems, and related computer-readable media, which use multiple blood marker values, including serum and plasma marker values, to aid in the diagnosis of the status or progress of a liver disease in a patient. The invention also provides methods and systems, and related computer-readable media, that use blood marker values, including serum and plasma marker values: (1) to screen for active ingredients useful in the treatment of a liver disease; (2) to aid in the selection of treatment regimens for patients that are predisposed to, or suffer from, liver disease; and (3) to aid in the design of clinical programs useful in monitoring the status or progress of liver disease in one or more patients.

Liver disease-related methods and systems

The present invention relates to monoclonal antibodies binding to the N-terminal procollagen (III) propeptide (PIIINP) molecule which is a proteolytic fragment emanating from the specific cleavage of procollagen (III) by N-proteinase after exocytosis and to an assay using these antibodies.

Monoclonal antibody and assay for detecting PIIINP

The present invention concerns a method for diagnosing liver fibrosis wherein two or more diagnostic markers are measured and the measurements are correlated by a mathematic algorithm characterized in that the diagnostic markers are selected from the group N-terminal procollagen III propeptide (PIIINP), Collagen IV, Collagen VI, Tenascin, Laminin, Hyaluronan, MMP-2, TIMP-1 and MMP-9/TIMP-1 complex. The algorithm can be used to predict the histological score of a liver biopsy.

Assessment of liver fibrosis scoring with serum marker algorithms

Growing community of inventors

Cologne, Germany

Mathias Gehrmann